The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma. The study investigators from City of Hope ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results